Garry Watts is to succeed Dr John Brown as non-executive chairman of BTG, an international specialist healthcare company, on 1 January 2012.
Watts is chairman of the Spire Healthcare group of private hospitals. He is also the senior independent director at Stagecoach Group and a non-executive director of Coca-Cola Enterprises.
He was chief executive of SSL International for seven years until its sale in November 2010 to Reckitt Benckiser. He was a member of the supervisory board of the UK's Medicines Healthcare Research Agency for 17 years until 2008 and is a former executive director of Medeva and Celltech. He was also a non-executive director of Protherics until its acquisition by BTG in December 2008.
Louise Makin, chief executive of BTG, commented: ‘On behalf of the board, I'd like to thank John for his enormous contribution to BTG’s development, including his overall stewardship of the business and the support he has given to us all throughout his tenure as chairman.
‘Garry brings a wealth of experience from the healthcare and other sectors that will be of great benefit to BTG and we all look forward to working with him.’
BTG names non-executive chairman
Former chief executive of SSL International joins healthcare firm
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
2011 nces focus on cancer therapies
The future of the pharma industry increasingly lies in drugs for diseases with smaller patient populations, and those targeted more precisely at specific patient sub-populations. Many of the new chemical entities approved in 2011 were targeted at cancer, diabetes and cardiovascular diseases, as well as bacterial and viral infections
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies